Lenzilumab - Humanigen

Drug Profile

Lenzilumab - Humanigen

Alternative Names: KB-003

Latest Information Update: 30 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator KaloBios Pharmaceuticals
  • Developer Humanigen; KaloBios Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Drug hypersensitivity
  • Phase I Chronic myelomonocytic leukaemia
  • Research Solid tumours
  • Discontinued Asthma; Rheumatoid arthritis

Most Recent Events

  • 30 May 2018 Phase-I/II clinical trials in Drug hypersensitivity (Prevention) (IV), prior to May 2018 (Humanigen pipeline, May 2018)
  • 16 Apr 2018 Humanigen and the University of Texas M. D. Anderson Cancer Center agree to co-develop lenzilumab to support chimeric antigen receptor T cell therapy
  • 15 Mar 2018 Humanigen completes enrolment in its phase I trial for Chronic myelomonocytic leukaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top